Evidence-based treatment of lipids in the elderly

Current Atherosclerosis Reports

Volumn 6, Issue 5, 2004, Pages 388-397

  Eimer, Micah J ^a   Stone, Neil J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ATORVASTATIN; CERIVASTATIN; CREATINE KINASE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

AGED; AORTA INTIMA; ARTERY CALCIFICATION; ATHEROSCLEROSIS; CANCER RISK; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; ECHOGRAPHY; EVIDENCE BASED MEDICINE; GERIATRIC CARE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LIVER TOXICITY; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; MYOGLOBINURIA; MYOPATHY; MYOSITIS; PATIENT SELECTION; PRIMARY PREVENTION; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 5444260201     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-004-0051-4     Document Type: Review

References (33)

1. Ko DT, Mamdani M, Alter DA: Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004, 291:1864-1870.
2. Grundy SM, Becker D, Clark LT, et al.: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
3. LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease a meta analysis of randomized controlled trials. JAMA 1999, 282:2340-2346.
4. Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary-heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
5. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998, 279:1615-1622.
6. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994, 344:1383-1389.
7. Long-term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349-1357.
8. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335:1001-1009.
9. Collins R, Armitage J, Parish S, et al.: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
10. Sever PS, Dalhof B, Poulter NR, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
11. Shepherd J, Blauw GJ, Murphy MB, et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360: 1623-1630.
12. ALLTHAT Investigators: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLA). JAMA 2002, 288: 2998-3007.
13. Cannon CP, Braunwald E, McCabe CH, et al.: Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350: 1495-1504.
14. Pasternak RC, Smith SC, Bairey-Merz CN, et al.: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002, 40:567-572.
15. Ballantyne CM, Corsini A, Davidson MH, et al.: Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003, 163:553-564.
16. Fried LF, Shlipak MG, Crump C, et al.: Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003, 41: 1364-1372.
17. Collins R, Armitage J, Parish S, et al.: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.
18. Tonelli M, Moye L, Sacks FM, et al.: Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003, 138:98-104.
19. Wenger NK: Dyslipidemia as a risk factor at elderly age. Am J Geriatr Cardiol 2004, 13(suppl 1):4-9.
20. Corti MC, Guralnik JM, Salive ME, et al.: HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA 1995, 274:539-544.
21. Marroquin OC, Kip KE, Kelley DE, et al., for the Women's Ischemia Syndrome Evaluation Investigators: Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation. Circulation 2004, 109:714-721.
22. Ariyo AA, Thach C, Tracy R: Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 2003, 349:2108-2115.
23. Foody JM, Milberg JA, Pearce GL, Sprecher DL: Lipoprotein(a) associated with coronary artery disease in older women: age and gender analysis. Atherosclerosis 2000, 153: 445-451.
24. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S: Report of the National Heart, Lung, and Blood Institute Workshop on lipoprotein(a) and cardiovascular disease: recent advances and future directions. Clin Chem 2003, 49:1785-1796.
25. Chaves PH, Kuller LH, O'Leary DH, et al.: Subclinical cardiovascular disease in older adults: insights from the cardiovascular health study. Am J Geriatr Cardiol 2004, 13:137-151.
26. Rumberger JA, Simons DB, Fitzpatrick LA, et al.: Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area: a histopathologic correlative study. Circulation 1995, 92:2157-2162.
27. Grundy SM: Coronary calcium as a risk factor: role in global risk assessment. J Am Coll Cardiol 2001, 37: 1512-1515.
28. Detrano RC, Wong ND, Doherty TM, et al.: Coronary calcium does not accurately predict near-term future coronary events in high-risk adults. Circulation 1999, 99:2633-2638.
29. Espeland MA, Evans GW, Wagenknecht LE, et al.: Site-specific progression of carotid artery intimal-medial thickness. Atherosclerosis 2003, 171:137-143.
30. van der Meer IM, Bots ML, Hofman A, et al.: Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation 2004, 109:1089-1094.
31. O'Leary DH, Polak JF, Kronmal RA, et al.: Carotid artery intima and media thicknes as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999, 340:14-22.
32. Hirsch AT, Criqui MH, Treat-Jacobson D, et al.: Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001, 286:1317-1324.
33. McDermott MM, Greenland P, Liu K, et al.: The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med 2002, 136:873-883.